1867 - 2034

Mount Sinai Hospital – A Phase 3,Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (*HER2 low or negative) (DESTINY-Breast06)

It seems we can’t find what you’re looking for. Perhaps searching can help.